Ind-Swift Ltd. - (Amalgamated)

₹15.76

0.9 (6.1%)

INDSWFTLTD Share Price

Pharmaceuticals & Biotechnology

As on August 13, 2025

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 85.04 Cr

P/E Ratio6

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	15.31	Bullish
10-DMA	15.87	Bearish
20-DMA	16.54	Bearish
50-DMA	16.88	Bearish
100-DMA	15.4	Bullish
200-DMA	18.41	Bearish

Historical Performance

1 Year

N/A

3 Years

-28%

5 Years

65.9%

10 Years

221.6%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2024	Mar-2023	Mar-2022	Mar-2018	Mar-2017
Net Sales	5,022	4,110	3,977	2,698	2,631
Total Expenditure	4,537	3,689	3,524	2,635	3,285
Other Income	580	119	235	146	137
Operating Profit	1,065	539	689	209	-517
Interest	629	598	572	115	163
Depreciation	271	287	321	346	357
Profit Before Tax	165	260	-196	-534	-3,634
Consolidated Net Profit	142	260	-200	-504	-3,727
Adjusted EPS	3	5	-4	-9	-69

Compounded Sales Growth

10 Years:10.5

5 Years:4.8

3 Years:4.8

TTM:4.1

Compounded Profit Growth

10 Years:-52.9

5 Years:-24.4

3 Years:-24.4

TTM:-11.4

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:N/A

Return on Equity

10 Years:N/A

5 Years:-68.8

3 Years:-3.7

last year:2.6

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2024	Mar-2023	Mar-2022	Mar-2018	Mar-2017
Share Capital	108	108	108	250	250
Total Reserves	-7,017	-7,155	-7,312	-6,882	-6,405
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	10,249	4,176	6,341	6,797	6,722
Other Current Liabilities	1,123	3,451	1,474	579	626
Short Term Borrowings	44	3,549	3,655	3,740	3,835
Total Liabilities	6,545	6,492	6,318	6,148	6,646
Capital Work in Progress	512	297	90	---	22
Long Term Loans & Advances	761	759	805	721	742
Currents Investments	---	---	---	---	---
Short Term Loans and Advances	430	467	466	478	428
Total Current Assets	3,418	2,734	2,424	1,861	2,064
Total Assets	6,545	6,492	6,318	6,148	6,646
Adjusted Book Value	-128	-130	-133	-125	-116

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a low PE of 6.0, which may indicate undervaluation or subdued growth expectations.
Over the last three years, the stock delivered a weak 3-year price CAGR of -26.7%, indicating poor shareholder returns.
The stock carries beta data is unavailable, making volatility assessment inconclusive.
In the last financial year, the company reported an EBITDA of ₹1065 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹5022 million, suggesting a mid-sized operation.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹

Current Value: ₹

No. of Shares: NaN (Approx)

Performance:%

NIFTY Performance: %

1 day Top Gainers